Israel Englander’s Abeona Therapeutics ABEO Stock Holding History

Israel Englander’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,000	Closed	-$424K	–	6033
2024 Q2	$424K	Buy	100,000 +70,000	+233%	+$357K	﹤0.01%	4695
2024 Q1	$218K	Buy	+30,000	New	+$190K	﹤0.01%	5332
2023 Q4	–	Sell	-42,900	Closed	-$181K	–	6008
2023 Q3	$181K	Sell	42,900 -3,100	-7%	-$11.7K	﹤0.01%	5164
2023 Q2	$185K	Buy	+46,000	New	+$161K	﹤0.01%	5147
2020 Q1	–	Sell	-12,912	Closed	-$1.06M	–	3774
2019 Q4	$1.06M	Buy	12,912 +2,912	+29%	+$205K	﹤0.01%	2979
2019 Q3	$565K	Buy	+10,000	New	+$749K	﹤0.01%	3186

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's ABEO Position: Q2 2026 in Review

Israel Englander reduced its Abeona Therapeutics (ABEO) stake by 50% in Q2 2026, selling an estimated $1.18M and leaving 211,335 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4140.

Israel Englander first reported a position in ABEO in Q1 2015 and has held it in 41 quarters since. The position peaked at $16.5M in Q2 2019. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Israel Englander held 211,335 shares of Abeona Therapeutics worth $1.31M as of Q2 2026.
Israel Englander sold 214,091 Abeona Therapeutics shares in Q2 2026, an estimated $1.18M.
Abeona Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #4140 holding.
Israel Englander first reported a position in Abeona Therapeutics in Q1 2015 and has held it in 41 quarters since.
Israel Englander's Abeona Therapeutics position peaked at $16.5M in Q2 2019.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.